Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:ARAV NASDAQ:CMRX NASDAQ:MRKR NASDAQ:PHAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.78-7.3%$1.75$0.46▼$7.49$9.52M0.181.28 million shs166,472 shsARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AMRKRMarker Therapeutics$0.95-1.0%$1.21$0.81▼$5.95$12.29M1.522.72 million shs153,953 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group0.00%-10.10%-58.12%+79.80%-19.82%ARAVARAVIVE0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%0.00%0.00%+893.02%MRKRMarker Therapeutics0.00%-0.48%-21.49%-34.48%-65.70%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.78-7.3%$1.75$0.46▼$7.49$9.52M0.181.28 million shs166,472 shsARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.94 million shsN/AMRKRMarker Therapeutics$0.95-1.0%$1.21$0.81▼$5.95$12.29M1.522.72 million shs153,953 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group0.00%-10.10%-58.12%+79.80%-19.82%ARAVARAVIVE0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%0.00%0.00%+893.02%MRKRMarker Therapeutics0.00%-0.48%-21.49%-34.48%-65.70%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/AARAVARAVIVE 0.00N/AN/AN/ACMRXChimerix 2.00Hold$8.53-0.08% DownsideMRKRMarker Therapeutics 3.50Strong Buy$13.171,285.96% UpsidePHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K22.15N/AN/A$2.20 per share0.81ARAVARAVIVE$9.14MN/AN/AN/AN/AN/ACMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94MRKRMarker Therapeutics$6.59M1.87N/AN/A$1.73 per share0.55PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/AN/AARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%N/AMRKRMarker Therapeutics-$10.73M-$1.37N/AN/AN/A-271.12%-114.59%-90.31%11/13/2025 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest CMRX, PHAS, MRKR, APM, and ARAV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MRKRMarker Therapeutics-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AARAVARAVIVEN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22ARAVARAVIVEN/AN/AN/ACMRXChimerixN/A6.336.33MRKRMarker TherapeuticsN/A3.453.45PHASPhaseBio PharmaceuticalsN/A0.470.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%ARAVARAVIVE35.80%CMRXChimerix45.42%MRKRMarker Therapeutics22.39%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%ARAVARAVIVE60.40%CMRXChimerix13.10%MRKRMarker Therapeutics7.80%PHASPhaseBio Pharmaceuticals9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableARAVARAVIVE20N/AN/ANo DataCMRXChimerix9093.80 million78.15 millionOptionableMRKRMarker Therapeutics6012.94 million11.93 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableCMRX, PHAS, MRKR, APM, and ARAV HeadlinesRecent News About These CompaniesPhio Pharma announces strategic initiative to create awareness of the comprehensive INTASYL siRNA portfolioJune 9, 2025 | pharmabiz.comPTicagrelor antidote safely, effectively restores platelet function and treats bleedingApril 1, 2025 | msn.comMedPharm appoints Bill Humphries as new CEOFebruary 6, 2025 | msn.comMedpharm Appoints Chief Executive OfficerFebruary 4, 2025 | contractpharma.comCPhaseBio Pharmaceuticals Inc.October 19, 2024 | thestreet.comPhiladelphia-area life sciences industry nears 900 layoffs since 2022October 11, 2024 | bizjournals.comPhaseBio Pharmaceuticals, Inc. (PHASQ)August 3, 2024 | ca.finance.yahoo.comModified Release Neurology Therapeutics Report 202…February 19, 2024 | pharmiweb.comPVelia Therapeutics Appoints Michael York as Chief Business OfficerDecember 14, 2023 | finance.yahoo.comLeading innovators in GLP-1 analogues for the pharmaceutical industryNovember 6, 2023 | pharmaceutical-technology.comPAlcami Announces CEO TransitionJune 5, 2023 | finance.yahoo.com8-K: PhaseBio Pharmaceuticals IncMay 12, 2023 | marketwatch.comAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsMarch 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finanznachrichten.deBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comCardiomyopathy Medication Market Size and Forecast till 2031March 22, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataFebruary 28, 2023 | marketwatch.comJi Xing obtains global rights to cardiovascular candidate from PhasebioFebruary 9, 2023 | bioworld.comBBankrupt PhaseBio settles with investor-partner, handing off late-stage drugJanuary 18, 2023 | endpts.comESFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJanuary 17, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025A Bull Case for Quantum Computing Stock Is Still AliveBy Gabriel Osorio-Mazilli | September 3, 2025Beyond DIY: Home Depot's Conquest of the Professional MarketBy Jeffrey Neal Johnson | September 10, 2025CMRX, PHAS, MRKR, APM, and ARAV Company DescriptionsAptorum Group NASDAQ:APM$1.78 -0.14 (-7.29%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.80 +0.02 (+1.40%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.ARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 09/19/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Chimerix NASDAQ:CMRXChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Marker Therapeutics NASDAQ:MRKR$0.95 -0.01 (-1.04%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.98 +0.03 (+3.58%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
